Abbott | ABT - Equity Capital And Reserves


Abbott reported $52.06B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Agilent USD 7.12B 214M Mar/2026
AtriCure USD 491.69M 242K Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Becton, Dickinson and Co. USD 24.13B 1.15B Mar/2026
Bio-Rad Laboratories USD 6.85B 602.3M Mar/2026
Boston Scientific USD 25.86B 1.63B Mar/2026
Cooper Companies USD 8.36B 124.7M Dec/2025
Danaher USD 52.95B 415M Mar/2026
Dexcom USD 2.96B 210.9M Mar/2026
Edwards Lifesciences USD 10.33B 10.1M Mar/2026
Globus Medical USD 4.73B 159.06M Mar/2026
Insulet USD 1.3B 212.6M Mar/2026
Integra LifeSciences USD 1.04B 1.06M Mar/2026
Intuitive Surgical USD 17.47B 349.5M Mar/2026
J&J USD 81.19B 358M Mar/2026
Medtronic USD 48.99B 128M Dec/2025
Merit Medical Systems USD 1.63B 42.42M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Smith & Nephew USD 5.54B 331M Dec/2025
Solventum Corp USD 4.97B 80M Mar/2026
Stryker USD 22.42B 635M Dec/2025
Tandem Diabetes Care USD 132.4M 22.77M Mar/2026
Teleflex USD 3.08B 40.33M Mar/2026
Terumo JPY 1.58T 62.18B Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Zimmer Biomet Holdings USD 12.68B 16.1M Mar/2026